History
Liver cirrhosis has long been recognized as "the end stage of chronic liver disease." Even in ancient medical records, symptoms such as jaundice, ascites, and vomiting of blood were repeatedly described, and it was regarded as a fatal condition linked to death. As medicine advanced, liver cirrhosis came to be defined not simply as the liver becoming hard but as a pathological state in which normal liver tissue is replaced by scar tissue (fibrosis) and regenerative nodules form in between, rearranging the very structure of the liver. In the early 19th century, the term "cirrhosis" became established based on the observation that a diseased liver looks yellow and rough, and later, biopsy and anatomical studies made the form of the disease clearer.
Since the 20th century, the history of liver cirrhosis has also been a history of "identifying causes" and "managing complications." Before viral hepatitis was identified, alcohol, malnutrition, and chronic hepatitis of unknown cause were explained in a mixed way, but once hepatitis B and C were discovered and could be diagnosed by blood tests, cause-specific management became possible. In addition, as understanding deepened of why complications such as portal hypertension, esophageal varices, and hepatic encephalopathy occur, standard treatments such as bleeding prevention, ascites treatment, and infection prevention were established.
Recent research summarizes that the view of liver cirrhosis only as "a completely irreversible condition" is being partially revised. When the cause is strongly suppressed or eliminated, fibrosis can improve to some extent, and in some patients the concept of "recompensation (a course of returning to stability)" is being discussed. In addition, a new framework is being emphasized in which the progression of liver cirrhosis is not simply a matter of the passage of time but is shaped by acute decompensation, infection and inflammatory responses, and changes in the gut-liver axis together.
Causes
Liver cirrhosis is closer to a "final common pathway" that appears as a result of various chronic liver diseases persisting for a long time than to a single disease. The most common causes are alcohol-related liver disease, hepatitis B, hepatitis C, and metabolic dysfunction-associated steatohepatitis. Fatty liver itself is common, but some cases progress to steatohepatitis accompanied by inflammation and fibrosis, which over time can lead to liver cirrhosis.
There are also various other causes. Immune abnormalities or bile duct diseases such as autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis can be causes, and genetic diseases (e.g., Wilson disease, hereditary hemochromatosis), drugs and toxic substances, and liver congestion due to chronic heart failure are also causes. It is not uncommon for a person to have more than one cause. For example, if a person drinks heavily and also has viral hepatitis, or has obesity and diabetes combined with drinking, the rate of progression can be faster.
Recent research summarizes that, as treatment of viral hepatitis has advanced worldwide, the burden of virus-related cirrhosis is decreasing in some regions, whereas a change is being observed in which the burden of steatohepatitis and alcohol-related cirrhosis is increasing due to rising obesity and drinking. In other words, "cause-specific prevention" is the key to preventing liver cirrhosis, and managing alcohol, obesity, and viral infection are the biggest pillars.
Genetic Epidemiology
Liver cirrhosis itself is not a single-gene disease, but genetic influences partly play a role in "why some people progress to fibrosis faster with the same exposure." In addition, among the causes of liver cirrhosis are cases in which a genetic disease is the direct cause. Hereditary hemochromatosis can cause liver damage through excessive accumulation of iron, and Wilson disease can progress to hepatitis and cirrhosis through accumulation of copper. Alpha-1 antitrypsin deficiency can also be a cause of liver damage.
However, in general clinical practice, the genetics of liver cirrhosis is approached not by "screening with genetic tests" but by suspecting and confirming the possibility of a specific genetic disease using family history and accompanying signs as clues. For example, genetic causes are evaluated when cirrhosis of unknown cause develops at a young age, when family members have a similar liver disease, or when there are findings suggesting abnormal iron or copper metabolism.
Recent research summarizes that metabolic factors such as obesity and diabetes have a large effect on the progression of liver fibrosis, but genetic susceptibility may partly play a role in the differences in the rate of progression between individuals. From the perspective of the general public, however, it is more important that "rather than a disease caused by genetics alone, lifestyle factors and exposures such as infection and drinking account for a much larger share."
General Epidemiology
Liver cirrhosis is one of the leading causes of death worldwide and accounts for a large share of deaths due to liver disease. In the past, viral hepatitis was an important cause and still accounts for a large share in many regions, but recently, increasing obesity and metabolic disease and increasing drinking are frequently cited as factors adding a new burden. The clinical course of liver cirrhosis is broadly described in terms of the "compensated phase" and the "decompensated phase." In the compensated phase, there are few or mild symptoms and daily life is possible, but once the disease moves into the decompensated phase, complications such as ascites, esophageal variceal bleeding, hepatic encephalopathy, and jaundice appear, and the risk of hospitalization and death increases greatly.
Recent research summarizes that the first event of transition to decompensation varies from person to person and that, because even "decompensation" is heterogeneous in form, the prognosis is not uniform. Another epidemiological key point is cancer. Because liver cirrhosis raises the risk of hepatocellular carcinoma, the need for surveillance through abdominal ultrasound and other tests at regular intervals has become established as the standard of care.
In liver cirrhosis, the point of transition from the compensated to the decompensated phase is the key turning point that determines survival. Delaying this transition as much as possible through early detection and treatment of the cause is the most important goal of management.
Pathogenesis
The pathogenesis of liver cirrhosis can be understood as "a vicious cycle in which, as the healing process of long-lasting liver injury repeats, scar tissue builds up excessively, and that scar tissue obstructs the liver's blood flow and bile flow, causing even greater damage." The liver is an organ with great regenerative capacity, but when injury repeats, it cannot fully recover to its normal structure and fibrosis accumulates. At this point, regenerative nodules form and the vascular structure of the liver becomes distorted, and as a result, resistance to blood flow into the liver increases.
This increase in blood flow resistance creates portal hypertension. When portal pressure rises, blood creates bypass routes, forming esophageal and gastric varices, followed by complications such as ascites, splenomegaly, and worsening kidney function. In addition, liver function itself declines, reducing detoxification, protein synthesis, and production of clotting factors, leading to problems such as jaundice, bleeding tendency, susceptibility to infection, and hepatic encephalopathy. At the cellular level, hepatic stellate cells play an important role. Normally they are cells that store vitamin A, but when they receive inflammatory signals, they turn into fibrosis-producing cells and deposit excessive matrix such as collagen.
Recent research summarizes that portal hypertension is not simply a "plumbing problem" but that, combined with systemic inflammation, changes in gut microbes, and increased intestinal barrier permeability, it can determine complications and organ failure. This multipathway understanding is providing the basis for discovering new treatment targets.
Symptoms
The symptoms of liver cirrhosis differ by stage. In the early compensated phase, there may be only nonspecific symptoms such as fatigue, loss of appetite, weight loss, and nausea, or no symptoms at all. For this reason, it is often discovered through tests during follow-up of the underlying disease (e.g., viral hepatitis, steatohepatitis). As it progresses to the decompensated phase, characteristic symptoms appear. Fluid may accumulate in the abdomen, causing it to swell (ascites), the legs may swell, and bruising and gum bleeding may occur easily. Jaundice, in which the skin and eyes turn yellow, and generalized itching may also accompany these.
Skin changes in which blood vessels appear spider-shaped, reddening of the palms, and, in men, breast enlargement or decreased sexual function may also appear. The most dangerous symptoms are signals of complications. Vomiting blood and black stools suggest the possibility of variceal bleeding, and if consciousness becomes clouded or the sleep-wake rhythm breaks down, hepatic encephalopathy should be suspected.
If fever and abdominal pain are present, infection of the ascites or other infections should be evaluated quickly. Because early symptoms are often nonspecific, it is important for people with chronic liver disease to be evaluated without delay when new symptoms develop.
Signs
The signs seen on blood tests, physical examination, and imaging tests can be summarized along two axes: "decreased liver function" and "portal hypertension." Decreased liver function can appear in forms such as elevated bilirubin (jaundice), decreased albumin (edema and ascites), and worsening coagulation values (bleeding tendency). Conversely, liver enzyme levels may not necessarily be high in advanced cirrhosis, so it is dangerous to underestimate the condition of the liver based on these values alone. Signs of portal hypertension include splenomegaly and low platelet counts, ascites, and varices.
On examination, findings such as a fluid wave from ascites, leg edema, dilated abdominal wall veins, and the tremor of hepatic encephalopathy (a flapping of the hands when the arms are outstretched) may be observed. On imaging tests, the surface of the liver may become nodular, part of the liver (the caudate lobe) may enlarge, and splenomegaly and ascites may be seen.
Recent research summarizes that elastography (ultrasound-based and magnetic resonance-based), which measures the "stiffness" of the liver and spleen, is increasingly used to estimate fibrosis and the risk of portal hypertension. Judging the course by liver enzyme levels alone is insufficient, and a comprehensive evaluation is needed.
Screening
Rather than targeting the entire general population, the realistic approach to screening for liver cirrhosis is to detect it early in high-risk groups. High-risk groups include patients with chronic hepatitis B or C, long-term heavy drinkers, patients with obesity or diabetes at high risk of metabolic dysfunction-associated steatohepatitis, patients with autoimmune liver disease, and patients with cholestatic liver disease. The first step in screening is blood tests and noninvasive indices. Along with basic tests such as liver enzymes, platelets, and albumin, indices that estimate the risk of fibrosis by combining blood values may be used.
The second is to estimate the "likelihood of advanced fibrosis/cirrhosis" by measuring the stiffness of the liver with elastography. Recent research summarizes that combining these noninvasive tests makes it possible to classify the level of risk in many patients without a liver biopsy and that they are useful for follow-up.
The reason screening leads directly to treatment is that, even if liver cirrhosis itself is difficult to reverse completely, treating the cause and preventing complications can reduce deaths and hospitalizations. Therefore, "detection during the asymptomatic period" is important.
Diagnosis
The diagnosis is made by combining the history (exposure to causes), blood tests, imaging tests, and, if necessary, biopsy. In the past, liver biopsy was the representative method for confirming the diagnosis, but now diagnosis and staging have become possible with fairly high accuracy using imaging, elastography, and blood indices. Recent research summarizes that, with the development of noninvasive diagnostic tools, the paradigm is shifting from "biopsy-centered" to "noninvasive assessment-centered." Among imaging tests, ultrasound is the most widely used, and computed tomography or magnetic resonance imaging is added if necessary.
Elastography is useful for estimating the degree of liver fibrosis and is also used to indirectly assess the risk of portal hypertension. The most direct method of measuring portal hypertension is hepatic venous pressure gradient measurement, but because it is invasive, it is performed selectively. Once liver cirrhosis is confirmed, "diagnosis of complications" must also proceed. Esophageal varices are checked with upper endoscopy, ascites is checked for infection with paracentesis if necessary, and regular ultrasound for hepatocellular carcinoma surveillance is included.
After liver cirrhosis is diagnosed, systematically evaluating whether complications are present and how severe they are is the core of treatment planning. Going beyond simply confirming cirrhosis, the degree of portal hypertension and decreased liver function must be evaluated comprehensively.
Treatment
Treatment consists of 1) treatment of the cause, 2) prevention and treatment of complications, 3) nutritional and lifestyle management, and 4) evaluation for liver transplantation. Treatment of the cause is the most important. If drinking is the cause, abstinence from alcohol is key, and for hepatitis B and C, antiviral treatment can slow progression. If the risk of metabolic dysfunction-associated steatohepatitis is high, weight loss and management of diabetes, lipids, and blood pressure are important. Recent research summarizes that treating the cause can lead to some improvement in fibrosis and may also be linked to the possibility of recompensation.
Complications related to portal hypertension are the central pillar of cirrhosis treatment. To prevent esophageal variceal bleeding, nonselective beta-blockers are used or endoscopic band ligation is performed. Ascites is treated with salt restriction and diuretics, and if it is not controlled, procedures such as repeated paracentesis or a portosystemic shunt are considered. For hepatic encephalopathy, precipitating factors are corrected and medications that reduce toxic substances in the intestine are used. Prevention and early treatment of infection are also important. Patients with cirrhosis have reduced immune function, so infections can easily become severe.
In addition, hepatocellular carcinoma surveillance (usually ultrasound at 6-month intervals, etc.) has become established as standard care. In cases of end-stage liver failure, recurrent decompensation, or intractable complications, liver transplantation can be a definitive treatment.
Prognosis
The prognosis varies greatly depending on "whether the disease is in the compensated or decompensated phase," "whether the cause can be corrected," "how severe portal hypertension and systemic inflammation are," and "whether cancer is present." In the compensated phase, patients can remain stable for a relatively long period, but once decompensation occurs, the risk of death increases greatly. Recent research summarizes that decompensation is not simply a single event but that acute decompensation, infection, and systemic inflammatory responses can recur and promote organ failure.
In particular, acute decompensation and acute-on-chronic liver failure have high short-term mortality, so early recognition and aggressive treatment are important. Clinical scores (based on blood tests), elastography, and imaging-based indices can be used to predict prognosis. In addition, treatment response, maintaining abstinence from alcohol, success in viral suppression, and results of weight and metabolic management affect long-term prognosis.
The most certain way to improve prognosis is to combine treatment of the cause with prevention of complications. Delaying the transition to decompensation through active management in the compensated phase is the key strategy that determines long-term survival.
Prevention
Prevention of liver cirrhosis is broadly divided into primary prevention (reducing exposure to causes so that liver damage does not begin) and secondary prevention (preventing progression to cirrhosis and complications in people who already have liver disease). The key elements of primary prevention are prevention of viral hepatitis (especially hepatitis B vaccination), safe injection and blood management, prevention of heavy drinking, and prevention and management of obesity and diabetes. It also includes reducing exposure to hepatotoxic drugs and toxic substances.
Secondary prevention means finding and treating patients with chronic liver disease early. For hepatitis C, eliminating the virus through treatment can slow the progression of liver damage, and for hepatitis B, viral suppression can lower the risk of cirrhosis and liver cancer. People at high risk of metabolic dysfunction-associated steatohepatitis reduce their risk of progression through weight loss and metabolic control. Recent research summarizes that the strategy of identifying high-risk groups early using noninvasive fibrosis tests (blood indices and elastography) is becoming more important.
Finally, there are preventive measures even after a diagnosis of cirrhosis. Standard care such as abstinence from alcohol, nutritional management, vaccination, infection prevention, prevention of variceal bleeding, and hepatocellular carcinoma surveillance corresponds to "prevention that reduces deaths."